Claims

1. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient aged ≥ 75 years, in an amount so that the levels of serum phosphate range from and including 5.5 mg/dL to < 7 mg/dL or range from and including 5.5 mg/dL to ≤9 mg/dL.

2. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient having a ECOG PS of 2, in an amount so that the levels of serum phosphate range from and including 5.5 mg/dL to < 7 mg/dL or range from and including 5.5 mg/dL to ≤9 mg/dL.

3. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient having a hemoglobin level <10 g/dL, in an amount so that the levels of serum phosphate range from and including 5.5 mg/dL to < 7 mg/dL or range from and including 5.5 mg/dL to ≤9 mg/dL.

4. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient having visceral metastases, in an amount so that the levels of serum phosphate range from and including 5.5 mg/dL to < 7 mg/dL or range from and including 5.5 mg/dL to ≤9 mg/dL.

5. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient having 2 or 3 Bellmunt risk factors, in an amount so that the levels of serum phosphate range from and including 5.5 mg/dL to < 7 mg/dL or range from and including 5.5 mg/dL to ≤9 mg/dL.

6. The use according to any one of claims 1 to 5 wherein the levels of serum phosphate range from and including 5.5 mg/dL to < 7 mg/dL.

7. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient aged ≥ 75 years, wherein the medicament comprises erdafitinib in an amount of 8 mg and wherein the medicament is for daily, in particular once daily, administration on a continuous basis.

8. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient having a ECOG PS of 2, wherein the medicament comprises erdafitinib in an

amount of 8 mg and wherein the medicament is for daily, in particular once daily, administration on a continuous basis.

9. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient having a hemoglobin level <10 g/dL, wherein the medicament comprises erdafitinib in an amount of 8 mg and wherein the medicament is for daily, in particular once daily, administration on a continuous basis.

10. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient having visceral metastases, wherein the medicament comprises erdafitinib in an amount of 8 mg and wherein the medicament is for daily, in particular once daily, administration on a continuous basis.

11. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient having 2 or 3 Bellmunt risk factors, wherein the medicament comprises erdafitinib in an amount of 8 mg and wherein the medicament is for daily, in particular once daily, administration on a continuous basis.

12. The use according to any one of the preceding claims wherein the cancer is urothelial cancer, bladder cancer, hepatocellular cancer, squamous cell carcinoma, or lung cancer.

13. The use according to claim 12 wherein the cancer is metastatic or surgically unresectable urothelial cancer.

14. The use according to claim 12 wherein the cancer is advanced or metastatic cholangiocarcinoma.

15. The use of erdafitinib in the manufacture of a medicament for the treatment of cancer in a cancer patient, wherein

a) the medicament comprises erdafitinib in an amount of 8 mg and wherein the medicament is for daily, in particular once daily, administration on a continuous basis;

b) the serum phosphate levels of the patient are to be measured on a treatment day during the first cycle of erdafitinib treatment, in particular on day 14 ± 2 days, more in particular on day 14, of erdafitinib administration;

c-1) when the serum phosphate levels are <5.5 mg/dL, the amount of erdafitinib in the medicament for daily, in particular once daily, administration on a continuous basis is increased to 9 mg;

c-2) when the serum phosphate levels range from and including 5.5 mg/dL to < 7 mg/dL, the patient remains on the 8 mg daily, in particular once daily, continuous treatment;

c-3) when the serum phosphate levels are ≥ 7 mg/dL, the erdafitinib treatment is to be interrupted temporarily until serum phosphate levels are <5.5 mg/dL and then erdafitinib treatment is to be re-started with 8 mg daily, in particular once daily, on a continuous basis;

and wherein the cancer patient, is a patient meeting one or more of the following criteria : : age ≥75 years; ECOG PS 2; hemoglobin <10 g/dL; visceral metastases, in particular of the liver, lung and/or bone; and 2 or 3 Bellmunt risk factors.

16. The use of erdafitinib in the manufacture of a medicament for the treatment of metastatic or surgically unresectable urothelial cancer harboring select FGFR genetic alterations (FGFR translocations or mutations) in a patient aged ≥ 75 years, wherein erdafitinib is to be administered in an amount of 8 mg daily, in particular once daily, on a continuous basis and wherein the daily amount of erdafitinib is to be administered as two pharmaceutical compositions, in particular two tablets, each comprising 4 mg of erdafitinib, or as two pharmaceutical compositions, in particular two tablets, one comprising 3 mg of erdafitinib and one comprising 5 mg of erdafitinib.

17. The use of erdafitinib in the manufacture of a medicament for the treatment of metastatic or surgically unresectable urothelial cancer harboring select FGFR genetic alterations (FGFR translocations or mutations) in a patient aged ≥ 75 years, wherein erdafitinib is to be administered in an amount of 9 mg daily, in particular once daily, on a continuous basis, and wherein the daily amount of erdafitinib is to be administered as three pharmaceutical compositions, in particular three tablets, each comprising 3 mg of erdafitinib, or as two pharmaceutical compositions, in particular two tablets, one comprising 4 mg of erdafitinib and one comprising 5 mg of erdafitinib.

18. The use of erdafitinib in the manufacture of a medicament for the treatment of metastatic or surgically unresectable urothelial cancer harboring select FGFR genetic alterations (FGFR translocations or mutations) in a patient having visceral metastases, wherein erdafitinib is to be administered in an amount of 8 mg daily, in particular once daily, on a continuous basis and wherein the daily amount of erdafitinib is to be administered as two pharmaceutical compositions, in particular two tablets, each comprising 4 mg of erdafitinib, or as two pharmaceutical compositions, in particular two tablets, one comprising 3 mg of erdafitinib and one comprising 5 mg of erdafitinib.

19. The use of erdafitinib in the manufacture of a medicament for the treatment of metastatic or surgically unresectable urothelial cancer harboring select FGFR genetic alterations (FGFR translocations or mutations) in a patient having visceral metastases, wherein erdafitinib is to be administered in an amount of 9 mg daily, in particular once daily, on a continuous basis, and wherein the daily amount of erdafitinib is to be administered as three pharmaceutical compositions, in particular three tablets, each comprising 3 mg of erdafitinib, or as two pharmaceutical compositions, in particular two tablets, one comprising 4 mg of erdafitinib and one comprising 5 mg of erdafitinib.

20. The use of erdafitinib in the manufacture of a medicament for the treatment of metastatic or surgically unresectable urothelial cancer harboring select FGFR genetic alterations (FGFR translocations or mutations) in a patient aged ≥ 75 years and having visceral metastases, wherein erdafitinib is to be administered in an amount of 8 mg daily, in particular once daily, on a continuous basis and wherein the daily amount of erdafitinib is to be administered as two pharmaceutical compositions, in particular two tablets, each comprising 4 mg of erdafitinib, or as two pharmaceutical compositions, in particular two tablets, one comprising 3 mg of erdafitinib and one comprising 5 mg of erdafitinib.

21. The use of erdafitinib in the manufacture of a medicament for the treatment of metastatic or surgically unresectable urothelial cancer harboring select FGFR genetic alterations (FGFR translocations or mutations) in a patient aged ≥ 75 years and having visceral metastases, wherein erdafitinib is to be administered in an amount of 9 mg daily, in particular once daily, on a continuous basis, and wherein the daily amount of erdafitinib is to be administered as three pharmaceutical compositions, in particular three tablets, each comprising 3 mg of erdafitinib, or as two pharmaceutical compositions, in particular two tablets, one comprising 4 mg of erdafitinib and one comprising 5 mg of erdafitinib.